F-RESCA-T4
Phase 3Small molecule
F-RESCA-T4 is one of 95 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
3
Indications
3
Total Trials
3
Active Trials
94
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Carboplatin Plus Paclitaxel
BayerPhase 3
HB1801
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Consolidative Therapy
SSun Yat-sen University
Phase 3
F-RESCA-T4
RRenJi Hospital
Phase 3
HLX17
Shanghai Henlius BiotechPhase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for F-RESCA-T4. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- RRenJi Hospital